Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

• BMS-986369 (Drug), also known as Golcadomide: Specified dose on specified days

Primary outcomes

• Maximum observed plasma concentration (Cmax) [Up to approximately 44 days]
• Time of maximum observed plasma concentration (Tmax) [Up to approximately 44 days]
• Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] [Up to approximately 44 days]

Secondary outcomes

• Incidence of adverse events (AEs) [Up to approximately 44 days]
• Incidence of serious adverse events (SAEs) [Up to approximately 44 days]
• Number of participants with physical examination abnormalities [Up to approximately 44 days]
• Number of participants with vital sign abnormalities [Up to approximately 44 days]
• Number of participants with electrocardiogram (ECG) abnormalities [Up to approximately 44 days]
• Number of participants with clinical safety laboratory test abnormalities [Up to approximately 44 days]

Sex: All, ages: 18 Years to 75 Years, accepts healthy volunteers

Inclusion Criteria for all Participants (Group A, Group B, Group C):

* Body mass index (BMI) between 18 and 40 kg/m\^2 (inclusive), and body weight ≥ 50 kg.

Inclusion Criteria for Participants with Moderate or Severe Hepatic Impairment (Group A and Group B):

* Participants have moderate HI (Group A), severe HI (Group B) or cirrhosis due to chronic hepatic disease and/or prior alcohol use.
* Participants have moderate (Group A) or severe (Group B) HI as defined by National Cancer Institute-Organ Dysfunction Working Group (NCI-ODWG) criteria.

Inclusion Criteria for a Matched Healthy Participant (Group C):

* Participants must have liver-related laboratory test results within the respective reference ranges or with clinically insignificant excursions as agreed by the investigator and the Sponsor Medical Monitor.
* Participants must be free of any clinically significant disease that would interfere with the study evaluations.

Exclusion Criteria for all Participants (Group A, Group B, and Group C):

* Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion (ADME).
* History of major surgery within 8 weeks before the study intervention administration.
* Any other clinically significant medical, psychiatric, and/or social reason, or other active issues, as determined by the investigator.
* Other protocol-defined Inclusion/Exclusion criteria apply.

• Bristol-Myers Squibb, Study director, Bristol-Myers Squibb